Keyphrases
30-day Mortality
22%
All-cause Mortality
21%
Antibiotic Duration
15%
Antibiotic Therapy
16%
Antibiotic Treatment
19%
Antibiotics
36%
Bacteremia
42%
Bacterial Infection
14%
Bloodstream Infection
30%
BNT162b2 Vaccine
14%
Carbapenem-resistant Acinetobacter Baumannii
16%
Carbapenems
17%
Clinical Failure
15%
Clinical Outcomes
33%
Clostridium Difficile Infection
17%
Colistin
32%
Combination Therapy
14%
Confidence Interval
68%
COVID-19
40%
External Validity
13%
Febrile Neutropenia
15%
Fever
18%
Gram-negative Bloodstream Infections
14%
Hospitalized Patients
17%
Infectious Diseases
29%
Israel
30%
Kidney Transplant Recipients
21%
Lactams
24%
Long COVID
15%
Meta-analysis
61%
Meta-analysis of Randomized Controlled Trials
32%
Methicillin-resistant Staphylococcus Aureus
15%
Monotherapy
20%
Multivariate Analysis
16%
No Significant Difference
15%
Odds Ratio
25%
Older Adults
30%
Prospective Cohort Study
17%
Pseudomonas Aeruginosa (P. aeruginosa)
13%
Randomized Clinical Trial
17%
Randomized Controlled Trial
69%
Relative Risk
21%
Retrospective Cohort Study
18%
Risk Factors
30%
Risk Ratio
20%
Severe Infection
16%
Staphylococcus Aureus Bacteremia
22%
Systematic Meta-analysis
69%
Urinary Tract Infection
15%
Vancomycin
25%
Pharmacology, Toxicology and Pharmaceutical Science
Acinetobacter Baumannii
12%
Adverse Event
20%
All Cause Mortality
25%
Antibiotic Therapy
29%
Antibiotics
43%
Antiinfective Agent
14%
Bacterial Infection
15%
Bloodstream Infection
83%
Carbapenem
39%
Carbapenem Derivative
12%
Clinical Trial
13%
Clostridium Difficile Infection
10%
Cohort Study
28%
Colistimethate
32%
Combination Therapy
15%
Cotrimoxazole
8%
COVID-19 Vaccine
8%
Cross-Sectional Study
12%
Diseases
30%
Enterobacteriaceae
7%
Febrile Neutropenia
14%
Gram Negative Bacterium
13%
Gram Negative Sepsis
11%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
9%
Immunogenicity
8%
Infection
89%
Infectious Agent
17%
Lactam
20%
Malignant Neoplasm
7%
Meropenem
15%
Methicillin Resistant Staphylococcus Aureus Infection
18%
Methicillin-Resistant Staphylococcus Aureus
15%
Monotherapy
20%
Observational Study
11%
Penicillinase
9%
Piperacillin Plus Tazobactam
10%
Placebo
8%
Prevalence
9%
Prospective Cohort Study
11%
Pseudomonas aeruginosa
15%
Quinolone Derivative
8%
Randomized Clinical Trial
19%
Randomized Controlled Trial
88%
Retrospective Study
37%
SARS Coronavirus
10%
Sepsis
18%
Staphylococcal Bacteremia
15%
Staphylococcus Aureus
11%
Urinary Tract Infection
14%
Vancomycin
24%
Medicine and Dentistry
Acinetobacter Baumannii
9%
Adverse Event
7%
All Cause Mortality
15%
Antibiotic Therapy
37%
Antibiotics
34%
Antiinfective Agent
20%
Arm
8%
Bacterial Infection
13%
Bloodstream Infection
75%
Carbapenem
28%
Clinical Trial
11%
Clostridium Difficile Infection
7%
Cohort Analysis
15%
Colistimethate
13%
COVID-19
38%
Cross Sectional Study
11%
Diseases
13%
Gram-Negative Bacteria
11%
Hematopoietic Cell
7%
Hemodialysis
8%
Immunosuppressive Treatment
9%
Infection
100%
Infectious Disease
18%
Intensive Care Unit
14%
Internal Medicine
8%
Kidney Graft
17%
Malignant Neoplasm
7%
Meropenem
9%
Meta-Analysis
46%
Methicillin Resistant Staphylococcus Aureus
8%
Monotherapy
10%
Multivariate Analysis
10%
Observational Study
13%
Odds Ratio
20%
Pathogen
20%
Piperacillin/Tazobactam
8%
Postcovid Syndrome
12%
Prospective Cohort Study
8%
Pseudomonas aeruginosa
11%
Randomized Clinical Trial
9%
Randomized Controlled Trial
55%
Retrospective Cohort Study
20%
Retrospective Study
46%
Sepsis
8%
Severe Acute Respiratory Syndrome Coronavirus 2
11%
Staphylococcal Bacteremia
10%
Subgroup Analysis
8%
Systematic Review
47%
Urinary System
8%
Urinary Tract Infection
12%